VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2019 | GAP study: nab-paclitaxel & gemcitabine in locally advanced, unresectable pancreatic cancer

Stefano Cascinu, University of Modena, Modena, Italy, gives an update on the GAP trial (NCT02043730), a GISCAD Phase II comparative randomized trial of nab-paclitaxel plus gemcitabine in locally advanced, unresectable pancreatic cancer (LAUPC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter